mAbxience SA - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Mabxience SA (mAbxience), a subsidiary of Chemo Espana SA, is a biotechnology company that research, develops and manufactures biosimilar monoclonal antibodies. The company develops biosimilars, which are used for the treatment and prevention of various diseases in onclology such as breast cancer, colon cancer, some types of lymphoma and autoimmune diseases. It carries out clinical follow-up through pharmacovigilance programs that allow the detection of delayed toxicities. mAbxience also offers technical transfer support and regulatory services. The company operates through its offices in Switzerland, Spain, Argentina and Uruguay. mAbxience is headquartered in Lugano, Switzerland.

mAbxience SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 4
List of Figures 4
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
mAbxience SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
mAbxience SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
mAbxience SA, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Amneal Pharma Enters into Licensing Agreement with mAbxience 10
mAbxience Partners with World Health Organization and Utrecht Centre of Excellence for Affordable Biotherapeutics for Public Health 11
EPIRUS Biopharma Enters into Distribution Agreement with mAbxience 12
Licensing Agreements 13
Libbs Farma Enters Into Licensing Agreement With mAbxience For Biosimilar Monoclonal Antibodies 13
Stada Arzneimittel to Enter into Licensing Agreement with mAbxience 14
Acquisition 15
mAbxience Acquires GH Genhelix for USD13.5 Million 15
mAbxience SA - Key Competitors 16
mAbxience SA - Key Employees 17
mAbxience SA - Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List Of Tables


mAbxience SA, Pharmaceuticals & Healthcare, Key Facts 2
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
mAbxience SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
mAbxience SA, Deals By Therapy Area, 2012 to YTD 2018 8
mAbxience SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Amneal Pharma Enters into Licensing Agreement with mAbxience 10
mAbxience Partners with World Health Organization and Utrecht Centre of Excellence for Affordable Biotherapeutics for Public Health 11
EPIRUS Biopharma Enters into Distribution Agreement with mAbxience 12
Libbs Farma Enters Into Licensing Agreement With mAbxience For Biosimilar Monoclonal Antibodies 13
Stada Arzneimittel to Enter into Licensing Agreement with mAbxience 14
mAbxience Acquires GH Genhelix for USD13.5 Million 15
mAbxience SA, Key Competitors 16
mAbxience SA, Key Employees 17
mAbxience SA, Other Locations 18
mAbxience SA, Subsidiaries 18

List Of Figures


mAbxience SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
mAbxience SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

mAbxience SA - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Mabxience SA (mAbxience), a subsidiary of Chemo Espana SA, is a biotechnology company that research, develops and manufactures biosimilar monoclonal antibodies. The company develops biosimilars, which are used for the

USD 250 View Report

mAbxience SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Mabxience SA (mAbxience), a subsidiary of Chemo Espana SA, is a biotechnology company that research, develops and manufactures biosimilar monoclonal antibodies. The company develops biosimilars, which are used for the

USD 250 View Report

Natixis SA - Strategy, SWOT and Corporate Finance Report

Natixis SA - Strategy, SWOT and Corporate Finance Report market research report available in single user pdf license with Aarkstore Enterprise at USD 175

USD 175 View Report

Itau Unibanco Holding SA - Strategy, SWOT and Corporate Finance Report

Itau Unibanco Holding SA - Strategy, SWOT and Corporate Finance Report market research report available in single user pdf license with Aarkstore Enterprise at USD 175

USD 175 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available